AZD 6738

Drug Profile

AZD 6738

Alternative Names: AZD6738

Latest Information Update: 06 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; University of Pennsylvania
  • Class Antineoplastics; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Chronic lymphocytic leukaemia
  • Preclinical Diffuse large B cell lymphoma
  • No development reported B cell lymphoma; Lymphoid leukaemia

Most Recent Events

  • 04 Apr 2018 Preclinical trials in Diffuse large B cell lymphoma (Combination therapy) in USA (PO), prior to April 2018
  • 09 Mar 2018 Phase-II clinical trials in Ovarian cancer (Second-line therapy or greater, Recurrent, Combination therapy) in USA (PO) (NCT03462342)
  • 19 Feb 2018 Phase-II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03330847)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top